Investment Thesis
Artivion demonstrates strong revenue growth and excellent gross margins, but is operationally unprofitable with negative free cash flow (-$6.8M) and critically weak interest coverage (0.2x), indicating inability to service debt from operations. The severe disconnect between 64.9% gross margins and 1.2% net margins reflects significant operating inefficiencies that are not improving despite 13.6% revenue growth.
Strengths
- Strong gross margins of 64.9% indicate product value and pricing power
- Revenue growth of 13.6% YoY shows market demand in medical device sector
- Solid short-term liquidity with current ratio of 3.86x and quick ratio of 2.80x
Risks
- Negative free cash flow of -$6.8M indicates company is burning cash despite top-line growth
- Interest coverage ratio of 0.2x is critically low - operating income insufficient to cover debt service
- Net profitability severely compressed (1.2% margin) with minimal ROE (0.3%) and ROA (0.2%), indicating operational distress
- Operating expenses consume 59.9% of revenue despite healthy gross margins, suggesting structural inefficiencies
- Operating cash flow of only $1.2M on $116.3M revenue demonstrates poor cash conversion quality
Key Metrics to Watch
- Free cash flow trajectory and return to positive territory
- Operating margin expansion and OpEx rationalization efforts
- Debt service coverage ratio and refinancing capability given interest coverage constraints
- Operating cash flow conversion rate relative to net income
Financial Metrics
Revenue
116.3M
Net Income
1.4M
EPS (Diluted)
$0.03
Free Cash Flow
-6.8M
Total Assets
883.2M
Cash
55.8M
Profitability Ratios
Gross Margin
64.9%
Operating Margin
5.0%
Net Margin
1.2%
ROE
0.3%
ROA
0.2%
FCF Margin
-5.9%
Balance Sheet & Liquidity
Current Ratio
3.86x
Quick Ratio
2.80x
Debt/Equity
0.48x
Debt/Assets
49.0%
Interest Coverage
0.24x
Long-term Debt
215.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T08:01:51.480428 |
Data as of: 2026-03-31 |
Powered by Claude AI